作者
Minesh P Mehta, Patrick Rodrigus, CHJ Terhaard, Aroor Rao, John Suh, Wilson Roa, Luis Souhami, Andrea Bezjak, Mark Leibenhaut, Ritsuko Komaki, Christopher Schultz, Robert Timmerman, Walter Curran, Jennifer Smith, See-Chun Phan, Richard A Miller, Markus F Renschler
发表日期
2003/7/1
期刊
Journal of Clinical Oncology
卷号
21
期号
13
页码范围
2529-2536
出版商
American Society of Clinical Oncology
简介
Purpose: This phase III randomized trial evaluated survival as well as neurologic and neurocognitive function in patients with brain metastases from solid tumors receiving whole-brain radiation therapy (WBRT) with or without motexafin gadolinium (MGd).
Patients and Methods: Patients were randomly assigned to 30 Gy of WBRT ± 5 mg/kg/d MGd. Survival and time to neurologic progression determined by a blinded events review committee (ERC) were coprimary end points. Standardized investigator neurologic assessment and neurocognitive testing were evaluated.
Results: Four hundred one (251 non–small-cell lung cancer) patients were enrolled. There was no significant difference by treatment arm in survival (median, 5.2 months for MGd v 4.9 months for WBRT; P = .48) or time to neurologic progression (median, 9.5 months for MGd v 8.3 months for WBRT; P = .95). Treatment with MGd improved time to …
引用总数
学术搜索中的文章
MP Mehta, P Rodrigus, CHJ Terhaard, A Rao, J Suh… - Journal of Clinical Oncology, 2003